Guided Therapeutics (GTHP) Net Margin (2010 - 2025)
Guided Therapeutics (GTHP) posted Net Margin of 202.71% for Q4 2025, up 84.51% sequentially from 1308.33% in Q3 2025, and up 6979729.0% YoY from N/an in Q4 2024.
Guided Therapeutics (GTHP) Net Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has reported Net Margin for 16 years, with the latest figure at 202.71% in Q4 2025.
- Quarterly Net Margin rose 6979729.0% year-over-year to 202.71% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 430.25% (up 3658404.0% YoY) and the FY2025 annual result came in at 430.25%, up 3658404.0% from the prior year.
- Net Margin rose to 202.71% in Q4 2025 per GTHP's latest filing, from 1308.33% in the prior quarter.
- Over five years, Net Margin peaked at 202.71% in Q4 2025 and troughed at 70000.0% in Q4 2024.
- A 5-year average of 16039.17% and a median of 4025.0% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin plunged 6853438 bps in 2024, then surged 6979729 bps in 2025.
- Over 5 years, Net Margin stood at 848.33% in 2021, then plunged by 4041 bps to 35133.33% in 2022, then jumped by 96 bps to 1465.62% in 2023, then sank by 4676 bps to 70000.0% in 2024, then jumped by 100 bps to 202.71% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 202.71%, 1308.33%, and 731.62% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 7.37% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 19.37% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 16.67% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 19.04% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 10.84% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 6.47% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 13.47% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -202.71% |
| Sep 30, 2025 | -1,308.33% |
| Jun 30, 2025 | -731.62% |
| Dec 31, 2024 | -70,000.00% |
| Mar 31, 2024 | -7,350.00% |
| Dec 31, 2023 | -1,465.63% |
| Jun 30, 2023 | -3,645.45% |
| Mar 31, 2023 | -4,404.55% |
| Sep 30, 2022 | -35,133.33% |
| Jun 30, 2022 | -20,140.00% |
| Mar 31, 2022 | -21,100.00% |
| Dec 31, 2021 | -848.33% |
| Sep 30, 2021 | -268.42% |
| Jun 30, 2021 | -57,950.00% |
| Dec 31, 2020 | 8,476.00% |
| Sep 30, 2020 | 1,985.71% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -265,400.00% |
| Mar 31, 2019 | -1,244.44% |